Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer
Authors
Smyth, LMTamura, K
Oliveira, M
Ciruelos, EM
Mayer, IA
Sablin, MP
Biganzoli, L
Ambrose, HJ
Ashton, Jack
Barnicle, A
Cashell, DD
Corcoran, C
de Bruin, EC
Foxley, A
Hauser, J
Lindemann, JPO
Maudsley, R
McEwen, R
Moschetta, M
Pass, M
Rowlands, V
Schiavon, G
Banerji, U
Scaltriti, M
Taylor, BS
Chandarlapaty, S
Baselga, J
Hyman, DM
Affiliation
Medicine, Memorial Sloan Kettering Cancer CenterIssue Date
2020
Metadata
Show full item recordCitation
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.ccr-19-3953PubMed ID
32312891Additional Links
https://dx.doi.org/ 10.1158/1078-0432.ccr-19-3953Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.ccr-19-3953
Scopus Count
Collections
Related articles
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
- Authors: Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT
- Issue date: 2021 Feb 1
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
- Authors: Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S
- Issue date: 2021 Apr 16
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
- Authors: Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ
- Issue date: 2020 Mar
- BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
- Authors: Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M
- Issue date: 2019 May 1
- AKT Inhibition in Solid Tumors With AKT1 Mutations.
- Authors: Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS
- Issue date: 2017 Jul 10